Plain-English translation of NCT04927416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a special imaging scan called 68-Gallium-DOTATATE PET/CT can help doctors identify patients with advanced thyroid cancer who might respond well to a specific type of treatment called peptide receptor radionuclide therapy (PRRT). The scan looks for a marker called SSTR2 on cancer cells, which can help predict whether PRRT might work for you. This is a diagnostic study only—the scan itself is the focus, not the treatment.
Some patients with advanced thyroid cancer stop responding to radioactive iodine treatment, which is the standard approach. Doctors need a better way to identify which patients might benefit from other targeted therapies. This trial is trying to figure out whether this new imaging scan can predict which patients would be good candidates for PRRT.
You likely qualify if…
You likely don't qualify if…
You will come in for one imaging appointment where you receive an injection of a special tracer dye and then undergo a PET/CT scan—similar to other imaging tests you may have had. The entire visit typically takes a few hours. No additional visits or medications are required for this trial. Your doctors will use the scan images to look for markers that might predict how well certain treatments could work for you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States